Results 241 to 250 of about 626,622 (390)

Anti‐thrombotic therapy in patients with cancer at the end of life and associated clinical outcomes: A cohort study using population‐linked routinely collected data

open access: yesBritish Journal of Haematology, EarlyView.
Anti‐thrombotic therapy (ATT) prescribing patterns and outcomes in patients with poor prognosis cancer in Wales (2013–2021). This retrospective cohort study of 25 783 adults with cancer diagnoses associated with ≤1‐year life expectancy showed that 32% were receiving ATT at diagnosis, with 77% continuing until death.
Sarah J. Aldridge   +19 more
wiley   +1 more source

Improved outcomes in elderly patients with acute lymphoblastic leukaemia using a paediatric‐based protocol—A prospective study

open access: yesBritish Journal of Haematology, EarlyView.
In this population‐based study the relapse rates were remarkably low in patients reaching day 79 with active treatment, challenging the widely accepted belief that ALL is difficult to cure in the elderly. Summary Population data have shown that the prognosis for elderly patients with acute lymphoblastic leukaemia (ALL) is poor, even in the modern era ...
P. Quist‐Paulsen   +8 more
wiley   +1 more source

Predictors of Rehospitalization for Symptomatic Venous Thromboembolism after Total Hip Arthroplasty [PDF]

open access: bronze, 2000
Richard H. White   +4 more
openalex   +1 more source

The role of PSMA PET/CT in staging patients with intermediate‐risk prostate cancer

open access: yesBJU International, EarlyView.
Objective To synthesise data evaluating the diagnostic utility of prostate‐specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in intermediate‐risk prostate cancer (PCa), as its role in intermediate‐risk PCa remains uncertain.
Jacinta Bonaddio   +4 more
wiley   +1 more source

Amivantamab Plus Chemotherapy in Japanese Patients With EGFR Exon 20 Insertions NSCLC

open access: yesCancer Science, EarlyView.
This subpopulation analysis of the open‐label phase 3 trial (PAPILLION) evaluates the efficacy and safety of amivantamab–chemotherapy versus chemotherapy among Japanese patients with locally advanced or metastatic NSCLC with EGFR Exon 20ins mutation. Efficacy and safety results in this Japanese subpopulation were consistent with those in the overall ...
Satoru Kitazono   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy